NeurAxis (NRXS) vs. Its Rivals Head to Head Comparison

NeurAxis (NASDAQ:NRXS – Get Free Report) is one of 510 public companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its rivals? We will compare NeurAxis to related companies based on the strength of its institutional ownership, profitability, earnings, risk, analyst recommendations, valuation and dividends.

Insider & Institutional Ownership

11.8% of NeurAxis shares are owned by institutional investors. Comparatively, 40.3% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 21.1% of NeurAxis shares are owned by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares NeurAxis and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NeurAxis -492.76% N/A -641.25%
NeurAxis Competitors -191.42% -197.86% -21.83%

Risk and Volatility

NeurAxis has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500. Comparatively, NeurAxis’ rivals have a beta of 2.57, meaning that their average share price is 157% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for NeurAxis and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeurAxis 0 1 1 0 2.50
NeurAxis Competitors 4330 10559 18358 840 2.46

NeurAxis presently has a consensus price target of $13.00, indicating a potential upside of 208.06%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 28.73%. Given NeurAxis’ stronger consensus rating and higher probable upside, equities analysts plainly believe NeurAxis is more favorable than its rivals.

Earnings & Valuation

This table compares NeurAxis and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
NeurAxis $6.53 million -$14.63 million -3.98
NeurAxis Competitors $1.90 billion $136.32 million 5.94

NeurAxis’ rivals have higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

NeurAxis rivals beat NeurAxis on 9 of the 13 factors compared.

About NeurAxis

(Get Free Report)

NeurAxis, Inc. is a medical technology company focused on developing neuromodulation therapies for chronic and functional pain conditions. Its approach uses percutaneous electrical nerve field stimulation (PENFS), which delivers mild electrical impulses through nerves associated with the brain-gut pathway. The company’s lead product, IB-Stim, is a wearable, minimally invasive device cleared by the U.S. Food and Drug Administration for use as an adjunctive treatment for functional abdominal pain associated with irritable bowel syndrome in patients ages 11 to 18 who have not responded to conventional therapy.

Receive News & Ratings for NeurAxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeurAxis and related companies with MarketBeat.com's FREE daily email newsletter.